What type of study is this?

December 5, 2025MedicineOpen Access

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation

View Full Paper

Ask AI

Bookmark

Authors

AAAmal AlansariMinistry of Health AAAbdullah Al-HarbiPrince Sattam Bin Abdulaziz University KAKhaled AlshehriMinistry of Health

Discussion

Member takes

Implication

Meta-analysis assesses suicidal ideation in diabetes and obesity patients on GLP-1 agonists, suggesting no significant differences compared to other drugs.

Key Points

No significant difference in suicidal ideation on GLP-1 agonists versus other obesity medications.
Liraglutide associated with higher suicide risk compared to semaglutide, with odds ratio of 1.48.
Analysis included 12 studies assessing GLP-1 agonist effects in patients with obesity and diabetes.
Further randomized controlled trials are necessary to evaluate GLP-1 agonists' suicidality risks.

Cite This Study

Alansari et al. (2025) studied this question.

synapsesocial.com/papers/694022612d562116f28fc71e https://doi.org/10.1097/md.0000000000046173

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis assesses suicidal ideation in diabetes and obesity patients on GLP-1 agonists, suggesting no significant differences compared to other drugs.

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation

Discussion

Member takes

Implication

Key Points

Cite This Study

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider